Focus on AI-Driven Drug Discovery and Commercially Viable Brain-Computer Interface Companies: Key Players to Watch

　　【Pharmaceutical Network Market Analysis] Currently, the global technological revolution and industrial transformation are accelerating. "Artificial Intelligence+" has become the core engine driving the development of future industries, while AI drug discovery and brain-computer interfaces, as key tracks of future industries, are moving from the technology exploration phase to the critical stage of commercial implementation. Companies with mature commercial closed-loop capabilities will be able to build competitive barriers through technological innovation and achieve sustainable growth via profitable business models, becoming core players in the future industry landscape. Some institutions recommend keeping an eye on companies such as XtalPi Holdings, Insilico Medicine, Sunnyou Medical, and Better Life Medical.
 

AI-driven drug discovery is the core convergence area of "artificial intelligence + biomedicine," breaking the困境of long cycles, high costs, and low success rates in traditional drug development. In this field, XtalPi and Insilico Medicine stand out.
 

It is reported that JingTai Holdings has recently announced a series of positive developments. For instance, on March 2nd, ReviR Therapeutics ("ReviR"), an incubated company of JingTai Holdings, announced the completion of the first subject dosing for its small molecule drug pipeline RTX-117. This progress marks the official entry of RTX-117, a small molecule drug discovered through the collaboration between the company and ReviR using "AI+RNA" technology, into the clinical development stage. RTX-117 is expected to provide therapeutic options for patients with neurological diseases such as Charcot-Marie-Tooth disease (CMT) and Vanishing White Matter disease (VWM).
 

At the end of February, X-tal Therapeutics announced a collaboration with YolTech Therapeutics, a company specializing in in vivo gene editing and base editing technologies, to innovate in AI mRNA drug development. The two parties will focus on mRNA drugs and in vivo CAR-T therapies to jointly build an AI-driven "dry-wet experiment closed-loop" screening platform. On February 11, X-tal Therapeutics also announced the successful delivery of an intelligent and automated drug discovery and process optimization system to JW Pharmaceutical, a leading pharmaceutical company in South Korea.RobotThe laboratory has passed the acceptance test comprehensively. This cooperation is the scaled landing project of XtalPi's AI autonomous experimentation platform in overseas pharmaceutical enterprises.
 

Recently, Insilico Medicine, a clinical-stage biotech company driven by generative artificial intelligence, announced the pilot launch of its Automated Partnering System, an automated AI business development platform. This platform can directly handle preliminary due diligence inquiries based on a pre-integrated database, transforming the originally cumbersome manual communication process into an automated closed loop. It is reported that currently, Insilico Medicine has established multiple AI-driven drug discovery collaborations with pharmaceutical companies such as Fosun Pharma, Sanofi, Exelixis, Menarini, Hisun Pharmaceutical, Eli Lilly (LLY), Servier, Qilu Pharmaceutical, and Pharmstandard, and has delivered several R&D milestones.
 

Brain-computer interface, as another core track in "artificial intelligence + healthcare," is a key bridge connecting the brain with external devices and is expected to transform the development landscape of neurological disease treatment and rehabilitation. Companies like Sunnyou Medical and YolTech Therapeutics are increasing their investments in the brain-computer interface field.
 

As Sunnyou Medical disclosed in the investor relations activity record on January 14, the company, relying on its mature rehabilitation equipment matrix and integrating brain-computer interface technology, has achieved rapid upgrades. The core is to establish software connectivity, transforming passive rehabilitation devices into active ones with deep brain engagement, with a relatively short upgrade cycle. The company expects that by the end of June 2026, 27 core products will complete multimodal and multi-paradigm upgrades. It is anticipated that by the end of 2026, nearly 100 brain-computer interface products will be launched, with over 50 covering multimodal and multi-paradigm capabilities.
 

Sunnyou Medical recently stated in an institutional survey that the company is actively engaging in process exploration and technical cooperation with downstream innovative brain-computer interface clients, assisting them in achieving efficient commercialization from laboratory research to mass production. In the future, the company will continue to serve as a key supplier in the brain-computer interface field, providing downstream clients with comprehensive technical and product support covering invasive, semi-invasive, and non-invasive approaches. The company will further consolidate its first-mover advantage in invasive brain-computer interface implants, continuously increase R&D investment, deepen collaborative innovation with clients, and enhance the competitiveness of core products in terms of performance, reliability, and manufacturing processes.
 

Institutions indicate that, driven by multiple factors such as policy, capital, and technology, the commercialization process of brain-computer interfaces in China is accelerating. In the future, it will gradually progress from "neurorehabilitation" to "cognitive enhancement" and then to the era of "brain-computer integration."
 

Companies such as Crystal Tech Holdings, Insilico Medicine, Sunnyou Medical, and Better Life Medical have respectively formed differentiated commercial advantages in AI drug discovery and brain-computer interface fields, which will drive the practical application of industry technologies. In the future, with continuous technological iteration and growing market demand, companies with a closed-loop business model will continue to lead the way in the future industrial track. Some institutions indicate that under the wave of major AI-driven advancements, the pharmaceuticals sector is expected to unlock new growth logic, with rapid development anticipated in areas like brain-computer interfaces, early cancer screening, and AI healthcare.
 

Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to any person.